دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Natural History of? Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study
Basavaraj Kerur, MD, Eric I Benchimol, MD, Karoline Fiedler, BA, Marisa Stahl, MD, Jeffrey Hyams, MD
doi : 10.1093/ibd/izaa080
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 295–302
The incidence of very early onset inflammatory bowel disease (VEOIBD) is increasing, yet the phenotype and natural history of VEOIBD are not well described.
AXL Is a Potential Target for the Treatment of Intestinal Fibrosis
Calen A Steiner, MD, MS, Eva S Rodansky, MS, Laura A Johnson, Jeffrey A Berinstein, MD, MSc, Kelly C Cushing, MD MSCI
doi : 10.1093/ibd/izaa169
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 303–316
Fibrosis is the final common pathway to intestinal failure in Crohn’s disease, but no medical therapies exist to treat intestinal fibrosis. Activated myofibroblasts are key effector cells of fibrosis in multiple organ systems, including the intestine. AXL is a receptor tyrosine kinase that has been implicated in fibrogenic pathways involving myofibroblast activation. We aimed to investigate the AXL pathway as a potential target for the treatment of intestinal fibrosis.
Utility of the MARS-5 in Assessing Medication Adherence in IBD
James K Stone, MD, Leigh Anne Shafer, PhD, Lesley A Graff, PhD, Lisa Lix, PhD, Kelcie Witges, MPH
doi : 10.1093/ibd/izaa056
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 317–324
We aimed to validate the Medication Adherence Report Scale-5 (MARS-5) as a tool for assessing medication adherence in inflammatory bowel disease (IBD) and to determine predictors of medication adherence.
Predictors of High Health Care Utilization in Patients With Inflammatory Bowel Disease Within 1 Year of Establishing Specialist Care
Kenechukwu Chudy-Onwugaje, MBBS, MPH, Alexander P Mamunes, MD, David A Schwartz, MD, Sara Horst, MD, Raymond K Cross, MD, MS
doi : 10.1093/ibd/izaa070
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 325–335
A small proportion of patients with inflammatory bowel disease (IBD) consume a disproportionate amount of health care resources, with most of these spent on unplanned care in emergency room (ER) and hospital visits. Interventions in those at high risk in the outpatient setting could reduce the need for future inpatient care. We sought to describe the characteristics predictive of high health care utilization within 1 year after an initial IBD clinic encounter.
The Impact of Cholecystectomy on Long-Term Disease Outcomes and Quality of Life in Patients with Crohn’s Disease
Filippos Koutroumpakis, MD, Maham Lodhi, MD, Maaz Ahsan, Claudia Ramos Rivers, MD, Marc Schwartz, MD
doi : 10.1093/ibd/izaa076
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 336–343
Cholecystectomy (CCY) is one of the most frequently performed abdominal surgeries. However, the impact of CCY in clinical settings with altered gastrointestinal physiology and anatomy, such as Crohn’s disease (CD), has not been fully characterized. We sought to investigate clinical outcomes, disease severity, and quality of life of CD patients after CCY.
Responsiveness of the Patient-reported Outcomes Measurement Information System (PROMIS) Pediatric Measures to Changes in Disease Status and Quality of Life Among Children and Adolescents With Crohn’s Disease
Erica J Brenner, MD, Millie D Long, MD, MPH, Courtney M Mann, MA, CCRP, Wenli Chen, MS, MA, Camila Reyes, MS
doi : 10.1093/ibd/izaa083
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 344–351
PROMIS Pediatric domains provide self-reported measures of physical, emotional, and social health in children with chronic conditions. We evaluated the responsiveness of the PROMIS Pediatric measures to changes in disease activity and disease-specific, health-related quality of life (HRQOL) in children with Crohn’s disease (CD).
High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study
Sara van Gennep, MD, Sanne W Evers, Svend T Rietdijk, MD, Marieke E Gielen, MD, Nanne K H de Boer, MD, PhD
doi : 10.1093/ibd/izaa082
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 352–363
Work productivity (WP) loss includes absence from work (absenteeism) and productivity loss while working (presenteeism), which leads to high indirect costs in inflammatory bowel disease (IBD). Prior health economic analyses predominantly focused on absenteeism. Here we focus on presenteeism and assess predictors of WP loss, fatigue, and reduced health-related quality of life (HRQL).
Black and White Patients With Inflammatory Bowel Disease Show Similar Biologic Use Patterns With Medicaid Insurance
Edward L Barnes, MD, MPH, Christina M Bauer, MD, MPH, Robert S Sandler, MD, MPH, Michael D Kappelman, MD, MPH, Millie D Long, MD, MPH
doi : 10.1093/ibd/izaa090
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 364–370
Disparities in Objective Sleep Quality as Assessed Through Wrist Actigraphy in Minority Patients With Inflammatory Bowel Disease
Taha Qazi, MD, Alexander Smith, Megan Alexander, MPH, David Hammer, MD, Ting Wu, MD
doi : 10.1093/ibd/izaa106
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 371–378
Passive Smoking Increases the Risk for Intestinal Surgeries in Patients With Crohn’s Disease
Susanna Scharrer, MD, Donata Lissner, MD, Christian Primas, MD, Walter Reinisch, MD, Gottfried Novacek, MD
doi : 10.1093/ibd/izaa117
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 379–385
Smoking Cessation for Patients With Crohn Disease: Not Just for the Patient?
Rhys A John, MBChB, Richard B Gearry, MBChB, PhD
doi : 10.1093/ibd/izaa118
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 386–387
Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
Lauren Sahakian, Rhiannon T Filippone, Rhian Stavely, PhD, Ainsley M Robinson, PhD, Xu Sean Yan, PhD
doi : 10.1093/ibd/izaa161
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 388–406
IRF5 Acts as a Potential Therapeutic Marker in Inflammatory Bowel Diseases
Yonghong Yang, MD, Cui Zhang, MD, PhD, Dehuai Jing, MS, Heng He, MS, Xiaoyu Li, MD, PhD
doi : 10.1093/ibd/izaa200
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 407–417
Inflammatory Bowel Disease–Associated Changes in the Gut: Focus on Kazan Patients
Giuseppe Lo Sasso, PhD, Lusine Khachatryan, PhD, Athanasios Kondylis, PhD, James N D Battey, PhD, Nicolas Sierro, PhD
doi : 10.1093/ibd/izaa188
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 418–433
Evolution of Inflammatory Bowel Disease Research From a Bird’s-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics
Yiftach Barash, MD, MSc, Eyal Klang, MD, Noam Tau, MD, Shomron Ben-Horin, MD, Hussein Mahajna, MD
doi : 10.1093/ibd/izaa091
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 434–439
The Diverse Roles of the IL-36 Family in Gastrointestinal Inflammation and Resolution
Gemma Leon, MSc, Seamus Hussey, MB, Patrick T Walsh, PhD
doi : 10.1093/ibd/izaa232
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages 440–450
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
Jasmijn A M Sleutjes, MD, Annemarie C de Vries, MD, PhD, C Janneke van der Woude, MD, PhD, Jeanine E Roeters van Lennep, MD, PhD
doi : 10.1093/ibd/izaa295
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Page e25
Bowel Endometriosis Mimicking Crohn Disease
Arthur Foulon, MD, Raphael Pichois, MD, Charles Sabbagh, MD, PhD, Mathurin Fumery, MD, PhD
doi : 10.1093/ibd/izaa345
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e26–e27
A Case of Aseptic Renal Abscesses Associated With IBD
Shelly Soffer, MD, Shani Dahan, MD, Marina Maklakovski, MD, Amir Dagan, MD
doi : 10.1093/ibd/izaa284
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e28–e29
Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease
Rishika Chugh, MD, Deborah D Proctor, MD, Alicia Little, MD, PhD, Peggy Myung, MD, PhD, Shawn Cowper, MD
doi : 10.1093/ibd/izaa285
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e30–e31
Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series
Sailish Honap, MBChB, MRCP, Eva Sticova, MD, Eleni Theocharidou, PhD, Philip Berry, MD, Peter M Irving, MD
doi : 10.1093/ibd/izaa286
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e32–e34
Tofacitinib Induced Long-term Clinical, Endoscopic, and Histological Remission as a 6th Line Agent in Medically Refractory Ulcerative Colitis
Rocio Sedano, MD, Vipul Jairath, MD, PhD
doi : 10.1093/ibd/izaa296
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e35–e36
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study
Mohamed Attauabi, Johan Burisch, MD, PhD, Jakob Benedict Seidelin, MD, PhD, DMSc
doi : 10.1093/ibd/izaa297
Inflammatory Bowel Diseases, Volume 27, Issue 3, March 2021, Pages e37–e38
